Af­ter weath­er­ing fail­ure, re­jec­tion and lay­offs, Im­muno­Gen touts a new 'break­through' drug in its come­back plan

While the come­back plan for its lead drug is still up in the air, Im­muno­Gen says it has a sec­ond shot at an an­ti­body-drug con­ju­gate break­through.

The FDA has grant­ed break­through ther­a­py des­ig­na­tion to IMGN632, which tar­gets CD123, in re­lapsed or re­frac­to­ry blas­tic plas­ma­cy­toid den­drit­ic cell neo­plasm. The ag­gres­sive can­cer pri­mar­i­ly af­fects the skin, bone mar­row and lymph nodes.

Hav­ing pre­sent­ed ini­tial da­ta on the first-in-hu­man study at ASH 2019, the biotech said it will re­port up­dates from the dose ex­pan­sion co­hort in De­cem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER